No Data
No Data
Eli Lilly's Bad Quarter Doesn't Change the Long-Term Math on Obesity Bonanza -- WSJ
Roche's Antibody Against Alzheimer's Looks the Best Yet -- Barrons.com
AbbVie's Deal for Alzheimer's Antibody Raises Curtain for Roche News on Wednesday -- Barrons.com
Thursday, Halloween Market Falls in Scary Reaction to Earnings | Wall Street Today
Eli Lilly and Co Options Spot-On: On October 31st, 103.23K Contracts Were Traded, With 345.79K Open Interest
Barclays Maintains Overweight on Eli Lilly, Lowers Price Target to $975
No Data
No Data